共 29 条
- [21] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 TrialCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S307 - S308Facon, ThierryVenner, Christopher P.Bahlis, Nizar J.Attal, MichelOffner, FritzWhite, Darrell J.Karlin, LionelBenboubker, LotfiRigaudeau, SophieRodon, PhilippeVoog, EricYoon, Sung-SooSuzuki, KenshiShibayama, HirohikoZhang, XiaoquanYung, GodwinRifkin, Robert M.Moreau, PhilippeLonial, SagarKumar, Shaji K.Richardson, Paul G.Rajkumar, S. Vincent
- [22] A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor) plus G-CSF vs. G-CSF plus Placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantationBLOOD, 2007, 110 (11) : 137A - 138ADiPersio, JohnStadtmauer, Edward A.Nademanee, Auaypom P.Stiff, PatrickMicallef, IvanaAngell, J.Bridger, G.Calandra, Gary
- [23] Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901BLOOD, 2015, 126 (23)Scott, Bart L.Pasquini, Marcelo C.Logan, BrentWu, JuanDevine, StevePorter, David L.Maziarz, Richard T.Warlick, EricaFernandez, Hugo F.Alyea, Edwin P.Hamadani, MehdiBashey, AsadGiralt, Sergio A.Leifer, EricGeller, NancyLe-Rademacher, JenniferMendizabal, Adam M.Horowitz, Mary M.Deeg, H. JoachimHorwitz, Mitchell E.
- [24] Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (04) : 798 - 804Giralt, SergioCosta, Luciano J.Maloney, DavidKrishnan, AmritaFei, MingweiAntin, Joseph H.Brunstein, ClaudioGeller, NancyGoodman, StaceyHari, ParameswaranLogan, BrentLowsky, RobertQazilbash, Muzaffar H.Sahebi, FiroozehSomlo, GeorgeRowley, ScottVogl, Dan T.Vesole, David H.Pasquini, MarceloStadtmauer, Edward
- [25] Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase II Clinical TrialBLOOD, 2023, 142Yang, ChutingZheng, YalingSong, ChaoyangWu, MingWang, LeiZhou, XuanYue, ChunyanLin, XiaonanChen, JieZeng, HuiHuang, RuiLi, Yuhua
- [26] Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) TrialBLOOD, 2014, 124 (21)Alvarnas, J.Le Rademacher, J.Wang, Y.Little, Richard F.Akpek, G.Ayala, E.Devine, S.Kaplan, L.Noy, A.Popat, U.Thompson, J.Horowitz, M. H.Mendizabal, A.Navarro, W. H.Ambinder, R.
- [27] Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients With Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) TrialCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 13 - 14不详
- [28] Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD plus Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) PtsBLOOD, 2020, 136Paiva, BrunoManrique, IreneGiuliani, NicolaCavo, MicheleRojas, ChristineFu, WeijunMateos, Maria-VictoriaDimopoulos, Meletios A.Vorog, AlexanderLi, CongWang, BingxiaLabotka, Richard J.Dash, Ajeeta B.
- [29] Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and MethodsBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (10) : 1566 - 1572Saber, WaelLe Rademacher, JenniferSekeres, MikkaelLogan, BrentLewis, MoiraMendizabal, AdamLeifer, EricAppelbaum, Frederick R.Horowitz, Mary M.Nakamura, RyotaroCutler, Corey S.